United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $541.39, for a total value of $5,143,205.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares of the company’s stock, valued at $21,933,333.07. This trade represents a 19.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $549.57 on Tuesday. The company has a market capitalization of $23.33 billion, a PE ratio of 20.29, a price-to-earnings-growth ratio of 1.78 and a beta of 0.57. The business has a fifty day moving average price of $566.45 and a two-hundred day moving average price of $522.10. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter last year, the company earned $6.63 EPS. Sell-side analysts anticipate that United Therapeutics Corporation will post 26.84 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Leuthold Group LLC raised its holdings in shares of United Therapeutics by 41.4% during the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock valued at $5,200,000 after buying an additional 3,126 shares in the last quarter. Tobam raised its holdings in shares of United Therapeutics by 183.9% during the 3rd quarter. Tobam now owns 7,646 shares of the biotechnology company’s stock valued at $3,205,000 after buying an additional 4,953 shares in the last quarter. UBS Group AG grew its position in United Therapeutics by 45.3% during the 4th quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after acquiring an additional 70,445 shares during the last quarter. Perpetual Ltd bought a new position in United Therapeutics during the 4th quarter worth approximately $1,059,000. Finally, SG Americas Securities LLC grew its position in United Therapeutics by 88.6% during the 4th quarter. SG Americas Securities LLC now owns 26,960 shares of the biotechnology company’s stock worth $13,136,000 after acquiring an additional 12,663 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several research reports. HC Wainwright increased their price target on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Oppenheimer increased their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Cantor Fitzgerald increased their price target on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Morgan Stanley set a $516.00 price target on United Therapeutics in a research note on Thursday, May 7th. Finally, Raymond James Financial initiated coverage on United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 price target for the company. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.